A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study
Xiangfeng Lu,Zhongying Liu,Qingmei Cui,Fangchao Liu,Jianxin Li,Xiaoge Niu,Chong Shen,Dongsheng Hu,Keyong Huang,Jichun Chen,Xiaolong Xing,Yingxin Zhao,Fanghong Lu,Xiaoqing Liu,Jie Cao,Shufeng Chen,Hongxia Ma,Ling Yu,Xianping Wu,Xigui Wu,Ying Li,Huan Zhang,Xingbo Mo,Liancheng Zhao,Jianfeng Huang,Laiyuan Wang,Wanqing Wen,Xiao-Ou Shu,Fumihiko Takeuchi,Woon-Puay Koh,E Shyong Tai,Ching-Yu Cheng,Tien yin Wong,Xuling Chang,Mark Yan-Yee Chan,Wei Gao,Hong Zheng,Kexin Chen,Jing Chen,Jiang He,Clara Sze-man Tang,Karen Siu Ling Lam,Hung-fat Tse,Chloe Yu Yan Cheung,Atsushi Takahashi,Michiaki Kubo,Norihiro Kato,Chikashi Terao,Yoichiro Kamatani,Pak Chung Sham,Chew-Kiat Heng,Zhibin Hu,Y. Eugene Chen,Tangchun Wu,Hongbing Shen,Cristen J Willer,Dongfeng Gu
DOI: https://doi.org/10.1093/eurheartj/ehac093
IF: 39.3
2022-02-23
European Heart Journal
Abstract:Abstract Aims To construct a polygenic risk score (PRS) for coronary artery disease (CAD) and comprehensively evaluate its potential in clinical utility for primary prevention in Chinese populations. Methods and results Using meta-analytic approach and large genome-wide association results for CAD and CAD-related traits in East Asians, a PRS comprising 540 genetic variants was developed in a training set of 2800 patients with CAD and 2055 controls, and was further assessed for risk stratification for CAD integrating with the guideline-recommended clinical risk score in large prospective cohorts comprising 41 271 individuals. During a mean follow-up of 13.0 years, 1303 incident CAD cases were identified. Individuals with high PRS (the highest 20%) had about three-fold higher risk of CAD than the lowest 20% (hazard ratio 2.91, 95% confidence interval 2.43–3.49), with the lifetime risk of 15.9 and 5.8%, respectively. The addition of PRS to the clinical risk score yielded a modest yet significant improvement in C-statistic (1%) and net reclassification improvement (3.5%). We observed significant gradients in both 10-year and lifetime risk of CAD according to the PRS within each clinical risk strata. Particularly, when integrating high PRS, intermediate clinical risk individuals with uncertain clinical decision for intervention would reach the risk levels (10-year of 4.6 vs. 4.8%, lifetime of 17.9 vs. 16.6%) of high clinical risk individuals with intermediate (20–80%) PRS. Conclusion The PRS could stratify individuals into different trajectories of CAD risk, and further refine risk stratification for CAD within each clinical risk strata, demonstrating a great potential to identify high-risk individuals for targeted intervention in clinical utility.
cardiac & cardiovascular systems